The controversy of using PGA to define remission in RA
Nat Rev Rheumatol
.
2018 Mar 21;14(4):245.
doi: 10.1038/nrrheum.2018.35.
Authors
Ricardo J O Ferreira
1
2
,
Cátia Duarte
1
3
,
Mwidimi Ndosi
4
,
Maarten de Wit
5
6
,
Laure Gossec
7
8
,
J A P da Silva
1
3
Affiliations
1
Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
2
Health Sciences Research Unit: Nursing (UICiSA:E), Coimbra, Portugal.
3
Clínica Universitária de Reumatologia, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
4
Department of Nursing and Midwifery, Faculty of Health and Applied Sciences, University of the West of England, Bristol, UK.
5
Patient research partner, EULAR standing committee of People with Arthritis/Rheumatism in Europe (PARE), Zurich, Switzerland.
6
Department of Medical Humanities, VU University Medical Centre, Amsterdam, Netherlands.
7
Sorbonne Universités, UPMC Univ. Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), Paris, France.
8
Rheumatology Department, AP-HP, Pitié-Salpetrière Hospital, Paris, France.
PMID:
29559716
DOI:
10.1038/nrrheum.2018.35
No abstract available
Publication types
Comment
MeSH terms
Antirheumatic Agents*
Arthritis, Rheumatoid*
Humans
Inflammation
Prostaglandins A
Substances
Antirheumatic Agents
Prostaglandins A